Brailski Kh, Chernev K, Etŭrska M, Donov M, Velev G
Vutr Boles. 1986;25(3):43-9.
The clinical effect from the treatment of 48 patients with carsil and 24 patients with legalon is studied. The patients were subdivided into three groups in the base of the clinical, laboratory-chemical and instrumental examination: light hepatic lesions--hepatic steatosis, chronic persisting hepatitis (ChPH), post-hepatitis states, chronic active hepatitis (ChAN) and cirrhosis of the liver (CL). Both preparations were administered 3 three times, 2 tablets daily for 3 months. The results obtained revealed that the bioflavonoid preparation carsil did not much differ in its clinical effect from the preparation legalon. The preparations carsil and legalon had a good effect, but not with statistical significance, on the subjective symptoms--pain, sense of heaviness and upper dyspeptic syndrome in the patients studied. Both preparations had a good effect on the biochemical indices: thymol test, SGOT, gamma-globulins, immunoglobulin G, blood bilirubin. The three month administration of carsil and legalon did not essentially change the histological findings in liver. The preparations carsil and legalon are indicated in light and moderate hepatic affections--hepatic steatosis, ChPH, post-hepatitis states. No contraindications have been reported for the administration of those preparations even in advanced hepatic disorders where they could be included as "basis" therapy.
对48例服用卡西尔(Carsil)和24例服用利加隆(Legalon)的患者的治疗临床效果进行了研究。根据临床、实验室化学和仪器检查,将患者分为三组:轻度肝脏病变——肝脂肪变性、慢性持续性肝炎(ChPH)、肝炎后状态、慢性活动性肝炎(ChAN)和肝硬化(CL)。两种制剂均每日服用3次,每次2片,共服用3个月。所得结果显示,生物类黄酮制剂卡西尔在临床效果上与制剂利加隆并无太大差异。卡西尔和利加隆制剂对所研究患者的主观症状——疼痛、沉重感和上消化道消化不良综合征有良好效果,但无统计学意义。两种制剂对生化指标:麝香草酚试验、谷草转氨酶、γ-球蛋白、免疫球蛋白G、血胆红素均有良好效果。服用卡西尔和利加隆3个月并未从根本上改变肝脏的组织学检查结果。卡西尔和利加隆制剂适用于轻度和中度肝脏疾病——肝脂肪变性、ChPH、肝炎后状态。即使在晚期肝脏疾病中,将这些制剂作为“基础”治疗纳入时,也未报告有任何禁忌证。